Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $15,053.58 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 24,678 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $0.61, for a total value of $15,053.58. Following the transaction, the director directly owned 2,368,849 shares in the company, valued at $1,444,997.89. The trade was a 1.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total transaction of $33,618.60.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $22,448.16.

Werewolf Therapeutics Stock Down 4.8%

Shares of HOWL traded down $0.03 during trading hours on Monday, hitting $0.57. The company had a trading volume of 1,049,698 shares, compared to its average volume of 414,643. The company has a market capitalization of $27.89 million, a PE ratio of -0.35 and a beta of 0.77. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a one year low of $0.56 and a one year high of $2.38. The company’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $1.25.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP grew its stake in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics in the third quarter worth about $304,000. Vanguard Group Inc. raised its stake in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the period. Finally, Bank of America Corp DE boosted its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analysts Set New Price Targets

HOWL has been the topic of a number of analyst reports. Citizens Jmp downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Bank of America decreased their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Finally, Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research note on Friday, December 19th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.